Global Migraine Drugs Market

Migraine Drugs Market Size, Share, Growth Analysis, By Treatment Class (Acute/Abortive Treatment, Preventive/Prophylactic Treatment), By Therapeutic Class (Triptans, Acetylcholine Inhibitors/Neurotoxins), By Route of Administration (Oral, Injectables), By Region - Industry Forecast 2024-2031.

Report ID: SQMIG35I2350 | Region: Global | Published Date: November, 2024
Pages: 207 | Tables: 94 | Figures: 71

Migraine Drugs Market Insights

Global Migraine Drugs Market size was valued at USD 3.89 Billion in 2022 and is poised to grow from USD 4.50 Billion in 2023 to USD 17.25 Billion by 2031, growing at a CAGR of 18.0% in the forecast period (2024-2031).

As the name suggests, migraine drugs are medicines that are mainly designed to alleviate or prevent migraine symptoms. The two major categories of these medications include acute medicines and preventive medicines, wherein acute medicines are used to cure the attacks that have lately begun, and preventive medicines lessen the frequency of severe attacks. The market is significantly driven by the growing awareness of effective preventive solutions, availability of improved diagnosis, and the launch of novel medications. Nonetheless, a few factors restraining the growth of the market include significantly priced novel treatments and possible side-effects that may create hesitation among physicians and patients for use. Yet, the market is expected to grow considerably in the forthcoming years owing to modernizations in drug development, inclination towards personalized medicine, and notable growth potential in the developing markets.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Migraine Drugs Market size was valued at USD 3.89 Billion in 2022 and is poised to grow from USD 4.50 Billion in 2023 to USD 17.25 Billion by 2031, growing at a CAGR of 18.0% in the forecast period (2024-2031).

The global migraine drugs market is a highly competitive global market driven by many international competitors. Prominent corporations with cutting-edge AI and ML technology are Google, IBM, Microsoft, and NVIDIA. To support a wide range of applications across industries, these industry experts concentrate on creating cutting-edge algorithms, scalable platforms, and reliable infrastructure. Rapid advances in technology, strategic alliances, and large expenditures on research and development define the competitive environment. 'Pfizer ', 'GlaxoSmithKline ', 'Allergan ', 'Amgen ', 'Eli Lilly ', 'Teva Pharma ', 'Biohaven Pharma ', 'Johnson & Johnson ', 'Valeant Pharma ', 'AbbVie Inc. ', 'Eli Lilly and Company ', 'Novartis International AG ', 'Biohaven Pharmaceuticals ', 'Boehringer Ingelheim ', 'Zynerba Pharmaceuticals ', 'Teva Pharmaceutical ', 'Hoffmann-La Roche Ltd ', 'Amgen ', 'AstraZeneca'

The introduction of novel drug categories like CGRP gepants and inhibitors represents major progress. These novel treatments provide deep targeted mechanisms and have proved their efficiency in lessening the severity and frequency of migraines. This is majorly propelling more improvements, thus market growth. Also, constant research in migraine pathophysiology is resulting in the development of modernized therapies. Improvements in interpreting the genetic and molecular basis of migraines are fueling the development of personalized treatments.

Development of CGRP Inhibitors: The CGRP (calcitonin gene-related peptide) inhibitors have gained popularity in less time for the treatment of migraine. Drugs, such as Aimovig (erenumab), Emgality (galcanezumab), and Ajovy (fremanezumab) have proven their efficacy in decreasing migraine frequency and severity. They have progressed as highly preferred options for preventive migraine treatment. These medicines offer quarterly or monthly dosing, offering sustained efficiency for chronic sufferers of chronic migraine.

Region-wise, North America is the dominating region among others and is expected to lead over the forecast period owing to the increasing cases of migraines and higher awareness of drugs among patients and healthcare professionals. This results in elevated demand for efficient treatments. Regional growth is also impacted by the presence of well-developed healthcare infrastructure that facilitates better distribution of migraine medicines and better access to multiple treatments. Also, the existence of a greater number of pharma companies that drive availability and innovations is notably affecting the growth of the market. The key players operating in the region include AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Boehringer Ingelheim, Novartis International AG, and more.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Migraine Drugs Market

Report ID: SQMIG35I2350

$5,300
BUY NOW GET FREE SAMPLE